STRICTLY CONFIDENTIAL · DISCLOSED UNDER NDA FICTIONAL DEMO DOCUMENT

ARANYA BIOTECH × NORTHWIND ANALYTICS · CONFIDENTIAL PACK V1

Project Halcyon

A privacy-first clinical data analytics platform that cuts adverse-event signal detection from weeks to hours across Aranya's oncology and cardiology trials.

Prepared 28 September 2026 | Owner: Aranya Biotech, Data Science | Classification: Confidential

01 · AT A GLANCE

What Halcyon delivers

Pilot results from two Phase II trials, January to August 2026.

38 h
Median time to safety signal
was 19 days

2.4 M
Pseudonymised records processed
14 trial sites

96.8%
Signal precision vs. manual review
+21 pts

0
Direct identifiers leave India
by design

02 · ARCHITECTURE

How data flows

Identifiers are removed inside India before any analytics. Only pseudonymised data reaches the model layer.



03 · DATA MODEL

Core tables

What is held, and how it is protected.

TABLE	KEY FIELDS	STATUS
`subject`	subject_token, site_id, age_band, sex	Pseudonymised
`identity_map`	subject_token, name, phone	Personal · vault only
`adverse_event`	ae_id, meddra_pt, onset_day, grade	Pseudonymised
`dose`	subject_token, arm, mg, cycle	Pseudonymised
`signal`	pt, ror, ci_low, posterior	Aggregate

04 · PILOT RESULTS

Signal detection by therapy area

Precision against blinded manual review.

05 · COMMERCIAL PROPOSAL

Pricing for Northwind

Annual licence, per active trial. Indicative and subject to contract.

Pilot

₹18 lakh

1 trial · 6 months

- Signal model
- Weekly reports

Portfolio

₹1.2 crore

Up to 8 trials · 1 year

- Real-time signals
- Sponsor dashboards
- Dedicated data scientist

Enterprise

On request

Unlimited trials

- On-premise deployment
- Custom models

06 · ROADMAP

From pilot to rollout

Proposed joint plan, subject to a definitive agreement.

Q4 2026

Integration

Connect Northwind's warehouse; validate tokenisation.

Q1 2027

Joint pilot

Two cardiology trials; weekly signal review.

Q2 2027

Validation

Independent audit; DPDP impact assessment.

Q3 2027

Rollout

Portfolio licence across eight trials.